Abstract
BackgroundImmune checkpoint blockade (ICB) is a promising cancer immunotherapy, among which targeting the PD-1/PD-L1 pathway has been one of the widely studied ICB strategies. Anti-PD-L1 antibodies targeted at cancer cells...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
